Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Immunitor Announces Placebo-Controlled Trial of Its Therapeutic AIDS Vaccine

13.12.2004


Immunitor USA Inc., announces that its licensed vaccine candidate V-1 Immunitor (V1) has shown promising results in Phase II, placebo-controlled, clinical trial involving 47 HIV-infected individuals (http://www.emediawire.com/releases/2004/12/emw186195.htm)

The study was published in the special December issue of the Journal of Clinical Virology – the official journal of The Pan American Society for Clinical Virology and The European Society for Clinical Virology. The abstract of the paper is now available on PubMed - the website of the National Library of Medicine http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15567095

At the end of 6-month study volunteers who were treated with V1 had statistically significant increase in CD4-positive T-cell numbers (p=0.01). However, in the placebo group that has received sham pills, the changes in T-cell counts failed to reach the significance threshold (p=0.33). The clinical potential of V1 was further supported by an elevation in CD4/CD8 ratio among V1 recipients and decline in CD4/CD8 ratio in patients on placebo. The average weight gain among patients on V1 was 1.8 kg while placebo group lost 0.5 kg. These results indicate that V1 can delay or reverse the HIV disease progression without any concurrent toxicity.



"Our published data supports earlier published, Phase I studies of V1 demonstrating increase in T-lymphocyte numbers, decrease in viral load, body weight gain, and improved survival of end-stage AIDS patients,” said Vichai Jirathitikal, the inventor of the oral vaccine technology. "The study provides additional evidence that this type of vaccine might ultimately be effective as a safe and effective treatment for AIDS and potentially other autoimmune diseases as well."

" The very first clinical study of V1 was published in 2002. In just two years we were able to achieve the major milestone in drug development process, which is the pivotal Phase II trial. We have accomplished this despite major and obvious difficulties and we are looking forward to confirm such results in Phase III clinical trial," said Dr. Aldar S. Bourinbaiar, CEO.

Due to toxicity and drug resistance problems associated with conventional antiviral chemotherapy, the therapeutic use of AIDS vaccines is receiving increased attention in the medical community. There has been considerable experience with this type of approach, with several dozen clinical trials reported over the last twenty years. While the immune response appeared to change as a result of therapeutic vaccination in most, if not all studies, there was no demonstrable clinical benefit. Despite this setback many clinical studies of various therapeutic vaccines are in progress, which may eventually help to identify an effective strategy.

V-1 Immunitor is an experimental AIDS vaccine made as an ordinary pill and comprises heat- and chemically-inactivated viral antigens derived from the pooled blood of HIV-positive donors. V1, which is taken orally on a daily basis, is thought to function by modulating the mucosal immune response. This innovative method of vaccine administration places the emphasis on oral tolerization of alloantigens delivered through the gut. V1 is the first therapeutic AIDS vaccine that has shown the clinical improvement in AIDS patients when administered orally.

Dr. Aldar S. Bourinbaiar | Immunitor USA Inc

More articles from Health and Medicine:

nachricht 'Icebreaker' protein opens genome for t cell development, Penn researchers find
21.02.2018 | University of Pennsylvania School of Medicine

nachricht Similarities found in cancer initiation in kidney, liver, stomach, pancreas
21.02.2018 | Washington University School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Researchers invent tiny, light-powered wires to modulate brain's electrical signals

21.02.2018 | Life Sciences

The “Holy Grail” of peptide chemistry: Making peptide active agents available orally

21.02.2018 | Life Sciences

Atomic structure of ultrasound material not what anyone expected

21.02.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>